Bristol-Myers Squibb finally has FDA approval for its CAR-T therapy liso-cel, which has been cleared by the US regulator as Breyanzi for certain forms of large B-cell lymphoma. The green light comes ...

Bristol-Myers Squibb posted a solid set of financial results for the third quarter, but shares slid on investor fears that a payout tied new product approvals was in jeopardy. BMS’ stock fell a little ...

When it comes to deals on Nintendo Switch 2 games, the Nintendo eShop will have Cyber Deals starting on November 20, running through December 3. The shop will feature "holiday offers on select games," ...

The study shows a significant drop in CRS and ICANS risk 15 days after liso-cel infusion, supporting reduced monitoring requirements. FDA updated guidelines now require patients to stay near ...

Nottingham Forest could find the door has opened on a player in whom they are claimed to have been ‘very interested’. That's according to Spanish outlet El Periodico Aragon who have written a story ...

Barcelona will look to secure their fourth league triumph of the campaign when they welcome Getafe to the Estadi Johan Cruyff Stadium for a Sunday evening showdown. The Catalan giants underlined their ...

The opening week of the 2025/26 season during the weekend witnessed a flurry of goals from new signings who debuted in their new clubs across the English Premier League, (EPL), Serie A and LaLiga ...

Liso Soldati, 34, is building a generation of young changemakers through entrepreneurship education and digital storytelling. Liso leads national innovation challenges and coordinates student ...

Update (7/24/25): Only a couple of days after the new Switch 2 Pokémon Legends: Z-A bundle was announced, you can now pre-order it at various retailers or pick up an existing Switch 2 bundle that's ...

Liso-cel therapy significantly improves response rates and survival outcomes in relapsed/refractory CLL/SLL patients compared to standard-of-care treatments. The TRANSCEND CLL 004 trial showed a 52.5% ...

Liso-cel achieved a 95.5% overall response rate and a 62.1% complete response rate in MZL patients after at least two prior therapies. The two-year overall survival rate for patients treated with liso ...